”The importance of stratification in a statistician’s August kitchen”

Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.

Effektiv och hygienisk nivåmätning med radar från OEM Automatic

OEM Automatic erbjuder radarnivågivare från Rosemount – en lösning för beröringsfri nivåmätning som kombinerar precision, pålitlighet och lång livslängd. Teknik...

Novo Nordisk köper antikropp – för miljardbelopp

Danska läkemedelsjätten Novo Nordisk har tecknat avtal med det amerikanska bioteknikföretaget Omeros Corporation om att förvärva och vidareutveckla en antikropp...

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

Första läkemedlet mot förlossningsdepression får grönt ljus i EU

EU-kommissionen har för första gången godkänt ett läkemedel mot förlossningsdepression, närmare bestämt amerikanska Biogens Zurzuvae.

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes th...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Halsfluss i fokus när Magnus Gisslén ryter vidare

Magnus Gissléns sågning av Folkhälsomyndigheten (FHM) fortsätter och nu riktar han ljuset mot användning av antibiotika vid halsfluss. Han kritiserar också nätv...

The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”

It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

Speed meets precision for high-density components

ZEISS METROTOM 800 320 kV.

Icelandic pharmaceutical company Alvotech to list on Nasdaq Stockholm

One of Iceland's largest companies, the pharmaceutical firm Alvotech, has announced its intention to list on Nasdaq Stockholm.

Charged with illegal pharmaceutical sales – alleged earnings of 23 million

For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

Strömhopp från Novos styrelse – extra stämma utlyst

Större delen av styrelsen i danska läkemedelsjätten Novo Nordisk hoppar av efter oenighet med huvudägaren Novo Nordisk Foundation.

Svenska forskare fann ”mellanform av parkinson och alzheimer”

Vissa patienter som får diagnosen Parkinsons sjukdom kan i själva verket ha en annan sjukdom som snarare liknar alzheimer. Det enligt en ny studie från Umeå och...

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

The Future of Swedish & Danish Life Science (2026)

Trump in new push to lower drug prices

U.S. President Donald Trump announced on Sunday that he plans to sign an executive order to lower the cost of prescription drugs to the same levels paid in othe...

Merck KGaA acquires American company in €3.0 billion deal

Germany’s Merck is completing the acquisition of Springwork Therapeutics for 3 billion euros.

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...